Lantus®

Phase 3

MYLAN (VTRS)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Type 2 Diabetes

LLYInsulin Efsitora Alfa

Phase 3

IONSISIS-GCGRRx- Dose Level 1

Drug Information

Target Indication

Type 2 Diabetes

Clinical Trial

NCT02227875

Last updated: 12/13/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/9/2000

Lantus

Treatment of diabetes mellitus in adults, adolescents and children aged two years and above

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

VTRS

MYLAN

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

MYL-1601D ProductPhase 3

Diabetes Mellitus, Type 1

venlafaxine ER 75 mg/day (fixed dose)Phase 3

Major Depressive Disorder

LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATIONPhase 3

Glaucoma, Primary Open Angle (POAG)

RevefenacinPhase 3

Chronic Obstructive Pulmonary Disease, COPD

Amlodipine/atorvastatin single pillPhase 3

Hypertension

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts